Prediction of lymphoma response to CAR T cells by deep learning-based image analysis.
Prediction of lymphoma response to CAR T cells by deep learning-based image analysis.
复制标题
DOI:
10.1371/journal.pone.0282573
复制
发表时间:
2023
期刊:
影响因子:
3.7
通讯作者:
中科院分区:
文献类型:
--
作者:
Clinical prognostic scoring systems have limited utility for predicting treatment outcomes in lymphomas. We therefore tested the feasibility of a deep-learning (DL)-based image analysis methodology on pre-treatment diagnostic computed tomography (dCT), low-dose CT (lCT), and 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) images and rule-based reasoning to predict treatment response to chimeric antigen receptor (CAR) T-cell therapy in B-cell lymphomas. Pre-treatment images of 770 lymph node lesions from 39 adult patients with B-cell lymphomas treated with CD19-directed CAR T-cells were analyzed. Transfer learning using a pre-trained neural network model, then retrained for a specific task, was used to predict lesion-level treatment responses from separate dCT, lCT, and FDG-PET images. Patient-level response analysis was performed by applying rule-based reasoning to lesion-level prediction results. Patient-level response prediction was also compared to prediction based on the international prognostic index (IPI) for diffuse large B-cell lymphoma. The average accuracy of lesion-level response prediction based on single whole dCT slice-based input was 0.82+0.05 with sensitivity 0.87+0.07, specificity 0.77+0.12, and AUC 0.91+0.03. Patient-level response prediction from dCT, using the “Majority 60%” rule, had accuracy 0.81, sensitivity 0.75, and specificity 0.88 using 12-month post-treatment patient response as the reference standard and outperformed response prediction based on IPI risk factors (accuracy 0.54, sensitivity 0.38, and specificity 0.61 (p = 0.046)). Prediction of treatment outcome in B-cell lymphomas from pre-treatment medical images using DL-based image analysis and rule-based reasoning is feasible. This approach can potentially provide clinically useful prognostic information for decision-making in advance of initiating CAR T-cell therapy.
登录
查看更多内容
DOI:
10.1073/pnas.1806579115
发表时间:
2018-08-14
影响因子:
11.1
作者:
Mei S;Montanari A;Nguyen PM
通讯作者:
Nguyen PM
DOI:
10.1056/nejmoa1707447
发表时间:
2017-12-28
期刊:
The New England journal of medicine
影响因子:
--
作者:
Neelapu SS;Locke FL;Bartlett NL;Lekakis LJ;Miklos DB;Jacobson CA;Braunschweig I;Oluwole OO;Siddiqi T;Lin Y;Timmerman JM;Stiff PJ;Friedberg JW;Flinn IW;Goy A;Hill BT;Smith MR;Deol A;Farooq U;McSweeney P;Munoz J;Avivi I;Castro JE;Westin JR;Chavez JC;Ghobadi A;Komanduri KV;Levy R;Jacobsen ED;Witzig TE;Reagan P;Bot A;Rossi J;Navale L;Jiang Y;Aycock J;Elias M;Chang D;Wiezorek J;Go WY
通讯作者:
Go WY
影响因子:
10.6
作者:
Sari, Can Taylan;Gunduz-Demir, Cigdem
通讯作者:
Gunduz-Demir, Cigdem
影响因子:
4.6
作者:
Minh Tuan Nguyen;Binh Van Nguyen;Kim, Kiseon
通讯作者:
Kim, Kiseon
影响因子:
3
作者:
Naito, Tatsuhiko;Nagashima, Yu;Shimizu, Jun
通讯作者:
Shimizu, Jun